Detalhe da pesquisa
1.
Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.
Br J Haematol
; 199(5): 707-719, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36017875
2.
COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study.
Br J Haematol
; 194(3): 646-650, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34028800
3.
A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis.
Amyloid
; 30(3): 290-296, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37216268
4.
NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma.
EClinicalMedicine
; 60: 102015, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37287870
5.
Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations-CONCORDE.
JCO Precis Oncol
; 6: e2200133, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36446040
6.
Clinical trial recruiters' experiences working with trial eligibility criteria: results of an exploratory, cross-sectional, online survey in the UK.
Trials
; 22(1): 736, 2021 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34689802
7.
A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia.
Trials
; 22(1): 38, 2021 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33419469
8.
CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer.
Clin Transl Radiat Oncol
; 25: 61-66, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-33072895
9.
GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial.
Trials
; 18(1): 353, 2017 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-28747208
10.
Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study.
BMJ Open
; 7(8): e017913, 2017 Aug 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28801444
11.
Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.
Trials
; 18(1): 387, 2017 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28830517
12.
Correction to: Clinical trial recruiters' experiences working with trial eligibility criteria: results of an exploratory, cross-sectional, online survey in the UK.
Trials
; 22(1): 862, 2021 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34844638
13.
Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.
Trials
; 17(1): 456, 2016 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27645620